Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: re: 10Q

re: 10Q...ttccr

posted on Jan 18, 2007 05:03PM
Actually, the correct way to look at it is PDS had expenses for the quarter of 2.8 million, most of which I'm sure was charges from Alliacense. This is assuming your numbers are correct, which I didn't double check. $16.15 million in revs minus 2.8 million in expense nets to 13.35 divided by 2 = 6.68 each to TPL and PTSC (assuming it's a 50/50 split, which I believe it is but don't remember 100%)
Share
New Message
Please login to post a reply